2024年 Scrip亞洲100強榜單

2024SCRIPASIA100

1SCRIPASIA100ForewordThe

Asia-Paci?c

region,

like

the

rest

of

the

world,

continues

to

move

back

to

some

form

of

post-pandemicnormality–

althoughnoteverythingisgoingasexpected.China

was

widely

forecast

to

experience

a

rapid

economic

rebound

following

the

lifting

of

its

tough

COVIDrestrictions

in

late

2022,

but

in

reality

is

recovering

more

slowly

than

predicted.

The

larger

challenges

mak-ing

the

headlines

include

weak

consumer

con?dence

and

spending,

high

unemployment

among

youngerworkers,a

simmeringpropertycrisisandsharesell-o?sbyforeigninvestors.Although

the

longer-term

impact

of

these

factors

on

the

pharma

sector

is

not

yet

clear,

a

renewed

anti-corruption

drive

in

the

health

arena

has

seen

many

companies

rapidly

reduce

sales

and

promotion

activi-ties.

While

many

foreign

pharma

?rms

continue

to

be

concerned

about

the

state

of

US-China

relations,

apositivesignisthattop-levelvisitsbyo?cialsareresumingisapossiblesignalthatgeopoliticaltensionsmaybetoppingout.Japan,

as

the

largest

mature

biopharma

market

in

the

region,

continues

along

in

a

less

dynamic

butpredictable

fashion,

research-based

industry

concerns

there

continuing

to

center

on

the

?ne-tuning

ofthereimbursementpricingsystemandoncontinuedregularone-o?pricecutsforfast-sellingproducts.Supplyshortagesinitiallystemmingfromqualityconcernscontinuetoplaguethegenericssector.WhileJapan’stop?rmsalreadyhaveawell-developedinternationalpresence,thefocusofSouthKorea’sindustry

now

seems

very

much

to

be

on

building

up

a

similar

global

footprint,

helped

by

multiple

govern-ment-supported

programs

and

steadily

rising

R&D

capabilities

for

novel

drugs.

This

push

for

innovation

isalsore?ectedinChina,whichcontinuestomakerapidsurgesinareassuchasantibody-drugconjugatesand

immune-oncology,

with

western

?rms

entering

multiple

licensing

deals

to

access

valuable

new

assets.India

continues

to

be

a

global

generics

powerhouse,

but

some

of

the

largest

companies

there

remainconcerned

about

pricing

pressures

in

the

US.

Alongside,

there

have

been

investments

in

new

technologies,markets

and

specialty

products,

with

in

some

cases

a

steady

build-up

in

original

R&D.

More

recently,

therehave

been

signs

that

some

prominent

founding

families

are

considering

stepping

back

as

their

companieseyethenextstageindevelopment.More

broadly,

moves

to

repatriate

supply

chain

links

are

continuing

as

a

legacy

of

the

pandemic,

as

doesthe

adoption

of

remote

and

digital

tools

that

was

accelerated

during

the

toughest

challenges

of

COVID-19.While

we’ve

seen

no

landmark

mega

M&A

deals

since

last

year’s

edition,

there

have

been

some

substantialasset-speci?c

alliances.

Takeda’s

late

2022

agreement

with

Nimbus

Therapeutics

for

the

Phase

II

TYK2inhibitorTAK-279wastheprimeexampleofthis,beingwortha

whopping$4billionupfront.This

introduction

necessarily

picks

out

only

some

of

the

key

top-line

trends

and,

as

always,

we

hope

thecarefully

curated

selection

of

data,

insights

and

analysis

in

this

year’s

Scrip

Asia

100,

including

extensivecontent

from

our

on-the-ground

team,

will

help

you

dig

deeper

into

these

and

other

issues

to

help

makesenseofthislarge,diverseandcomplexpartofthepharmaworld.Ian

HaydockEditor-in-Chief,APACCiteline2

SCRIPASIA100CONTENTSCo

nte

ntsSCRIP

ASIA

100CLINICAL

TRIALSMANUFACTURINGCHINA4121924293844496066BroughttoyoubyINDIAJAPANKOREASponsoredbyPOLICY

&

REGULATIONDIGITALEMERGING

MODALITIESSCRIP

ASIA

100

EDITORSJanelleHartMaireGerrardASIA

TEAMAnjuGhangurdeBrianYangAllstockimagesinthispublicationarecourtesyofunlessotherwisestated.AndreaCharlesDexterJieYanJungWonShinLisaTakagiEDITORS-IN-CHIEFDenisePeterson(Regulatory)EleanorMalone(Commercial)IanHaydock(Asia)Customer

ServicesVibhaRaviTel:

+44(0)2070175540or(US)TollFree:1

8009973892Email:

Subscriptions@DESIGNCarlaAntillRyanNelson(Medtech)To

subscribe,

visitEXECUTIVE

EDITORSCOMMERCIALAlexandraShimmings(Europe)MaryJoLa?er(US)PRODUCTIONCarlaAntillTo

advertise,

contactchristopher.keeling@EXECUTIVE

EDITORSREGULATORYScripispublishedbyPharmaIntelligenceUKLimited(Citeline).?

2023PharmaIntelligenceUKLimited(Citeline),a

Norstellacompany:Allrightsreserved.ISSN01437690NielsenHobbs(US)NeenaBrizmohun(Europe)SCRIPASIA100

3SponsoredbyRegulatory

Reforms

EnhanceChina’s

Biotech

Trial

Pote

nti

alLina

Feng,

Director,GlobalRegulatoryA?airs,ICONChinaQing

Liu,

SeniorDirector,ProjectManagement,ICONChinaChina

has

rapidly

established

itself

as

an

attractive

optionfor

clinical

trials,

with

activity

trending

upwards

year

on

yearover

the

last

decade.

In

fact,

for

the

?rst

time

in

2021

Chinaovertook

the

US

as

the

top

destination

for

trials,

with

3,795in

other

locations.

As

a

result,

biotech

companies

can

capital-ize

on

the

advantages

China

can

o?er

their

studies

in

earlydevelopmentandexpediteprogress.There

are

also

further

bene?ts

for

overseas

sponsors

wish-ing

to

access

the

Chinese

market

after

their

products

progressthrough

clinical

studies.

The

prior

requirement

stipulating

animported

product

must

be

authorized

in

its

country

of

originbefore

MAA

submission

in

China

has

now

been

removed.NMPA

has

also

introduced

measures

to

encourage

the

devel-opment

of

innovative

products

and

those

for

unmeet

clinicalneeds

(e.g.

rare

disease

and

pediatric

indications)

such

asbreakthroughprocedures,conditionalapprovalandpriorityreviewprocesses.AsChinaisthesecondlargesthealthcaremarket,

this

is

valuable

for

companies

looking

for

commercialsuccess

and

it

also

increases

prospects

for

Chinese

patientslookingforimprovedtreatmentoptions.new

clinical

trials

initiated

there

compared

to

3,310

in

the

US.1There

has

long

been

great

potential

for

international

bio-tech

companies

that

pursue

studies

in

China,

with

its

largepopulation

facilitating

reduced

patient

recruitment

timelinesand

lower

study

start-up

(SSU)

costs.

However,

the

complexregulatory

environment

may

have

dissuaded

some

sponsorsfrom

considering

China

as

a

study

location

for

multi-regionalclinical

trials

(MRCTs).

Now,

following

signi?cant

reformsand

the

Chinese

National

Medical

Products

Administration(NMPA)

becoming

a

regulatory

member

of

the

InternationalCouncil

for

Harmonization

(ICH)

of

Technical

Requirementsfor

Pharmaceuticals

for

Human

Use,

there

is

a

renewed

op-portunityforbiotechstoreap

thebene?tsoftrialsinChina.SOLUTIONS

EXIST

FOR

REMAINING

CHALLENGESWhile

the

reforms

made

to

clinical

trial

processes

in

China

arevery

encouraging

for

biotech

sponsors,

there

are

underlyingdistinctions

to

studies

carried

out

here

that

may

dissuadecompanies

from

considering

the

location.

Nevertheless,

therearewaystoovercometheseobstacles.OPTIMIZED

CLINICAL

TRIAL

APPLICATION&

REGISTRATION

PATHWAYSOnce

a

clinical

trial

application

(CTA)

has

been

accepted

forreview,timelinesforapprovalhavebeenstandardizedto60workingdaysunderthenewregulatoryframework.Thisisanotable

improvement

on

the

two-

to

three-year

period

it

couldpreviously

take.

Moreover,

sponsors

are

permitted

to

initiatestudies

if

no

objection

is

received

from

China’s

Center

forDrugEvaluation(CDE)inthattimeframe,placingtheburdenonreviewbodiesundera

tacitapprovalmodel.The

CDE

also

o?ers

multiple

channels

to

support

sponsorswith

studies

and

marketing

authorization

application

(MAA)submissions,

including

communication

meetings

to

clarifyany

uncertainties.

These

meetings

are

free

of

charge,

whichis

particularly

helpful

for

biotechs

looking

to

manage

their?nancialresourcescarefully.Local

treatment

practices

and

guidanceThere

are

local

nuances

to

treatment

practices

and

guidancein

China

that

international

sponsors

may

not

have

an

in-depthunderstandingof,especiallyifconductingtrialsintheregion

for

the

?rst

time.

For

this

reason,

it

is

very

importantto

involve

key

opinion

leaders

(KOLs)

as

early

as

possible.These

experts

can

provide

suggestions

on

protocol

design,support

communication

with

the

CDE,

recommend

principalinvestigators

(PIs),

help

with

site

identi?cation,

and

acceler-ateSSUtimelines.Additionally,

restrictions

on

registering

imported

medicinalproducts

for

use

in

clinical

trials

have

been

reduced,

enablingsponsors

to

conduct

research

in

China

much

earlier.

Previ-ously,

in

order

to

be

used

in

a

study

in

China,

the

productneeded

to

have

already

commenced

Phase

II

or

III

trials

inother

countries.

However,

under

revised

guidance,

sponsorscan

now

start

Phase

I

studies

in

China

in

parallel

with

thoseWhen

identifying

sites,

biotechs

must

note

that

in

Chinamost

are

independent

and,

consequently,

their

requirementsdi?er.

Even

the

same

site

may

change

their

conditions

fromone

year

to

the

next,

so

it

is

critical

that

sponsors

check

be-fore

any

submission.

Again,

KOLs

and

local

expertise

are

veryhelpfulwhennavigatingthesecomplexities.4

SCRIPASIA100During

the

trial,

it

is

also

best

to

assign

a

medical

monitorbasedinChina,astheycanupholdtriale?ciencybyremov-ing

language

and

time-zone

barriers

to

quickly

address

anyquestions

that

may

arise

from

the

PI.

If

sponsors

have

localpresence

this

could

be

a

member

of

their

own

team,

but

asmany

US-

or

Europe-headquartered

biotechs

do

not

have

suchworkforces,

contract

research

organizations

(CROs)

can

assist.BENEFITS

AWAIT

FOR

BIOTECHSWhile

there

are

no

doubt

challenges

to

conducting

trials

inChina

for

biotechs

based

in

the

US

and

Europe,

for

those

thatpersevere

there

are

clear

bene?ts

to

be

realized.

China

isthemostpopulouscountryintheworld,butithasrelativelyuntreated

patients

in

a

number

of

key

therapeutic

areas

suchas

immuno-oncology

and

chronic

diseases.

This

leads

to2recruitment

timelines

that

are

estimated

to

be

around

twoto

three

times

faster,

which

is

critical

for

biotech

companiesracing

to

generate

positive

clinical

data

and

secure

furtherinvestment.CostsarealsolowerthaninthehighlycompetitiveUSandEuropean

markets

for

trial

start-up

and

enrolment.

Generally,even

at

top

urban

medical

centers,

direct

costs

are

aroundCompeting

trialsWhile

the

exponential

growth

of

trials

in

China

has

greatlyincreased

site

and

PI

experience,

as

this

continues

some

spon-sors

may

?nd

themselves

competing

to

secure

availability.Onestrategyistotargetmoresitesinwhatmaybereferredto

as

“Tier

2/3”

cities

instead

of

highly

oversubscribed

“Tier1”

cities.

While

these

sites

may

not

have

as

much

direct

ex-perience,

training

can

be

provided

to

ensure

studies

still

rune?ectively

and

they

will

likely

have

untapped

patient

poolswhichcan

accelerateenrolment.30%

lower

than

in

the

US.

For

early-stage

sponsors

progress-2ing

one

of

their

?rst

assets

to

the

clinic,

every

bit

of

?nancingneeds

to

stretch

as

far

as

it

can,

so

savings

such

as

this

couldbepivotaltomovethroughdevelopment.There

are

also

recruitment

and

retention

services

availablefor

sponsors

should

they

struggle

with

enrolment.

Partnershave

their

own

databases

and

networks

of

community

hos-pitals

and

clinics

which

biotechs

would

otherwise

not

be

abletoaccess.ManyCROsnowhavethiscapabilityin-house,butthey

can

also

form

local

partnerships

with

specialist

provid-ers

to

build

targeted

strategies

for

recruitment,

dependingonthetherapyandpatientsrequired.Mostofthebarrierstoachievingtheseadvantagescanbeovercome

with

understanding

of

the

Chinese

trial

environ-ment

and

requirements.

For

biotechs

without

a

local

pres-ence

in

China,

it

is

highly

unlikely

they

will

already

have

thisin-house,

so

partnerships

with

specialists

are

the

way

forward.Established

CROs

can

utilize

their

experience

and

exper-tise

to

guide

international

sponsors

through

the

nuances

ofChina’s

regulatory

and

clinical

processes,

to

avoid

any

delaysor

errors

that

require

rectifying

at

a

later

stage.

As

Chinacontinues

to

gain

momentum

as

a

key

study

location

andrequirements

continue

to

evolve,

this

will

be

key

to

ensuringtrialsuccess.Communication

and

time

zone

di?erencesOne

of

the

key

concerns

from

US-

and

Europe-based

biotechcompanies

when

considering

trials

in

China

is

the

lack

ofcontrol

and

communication

they

may

have,

due

to

signi?canttime

zone

di?erences

and

language

barriers.

As

a

result,

it

isrecommendedthatalltrialshavea

China-basedclinicaltrialmanager

(CTM)

who

is

familiar

with

local

practices,

culture,anddialect,whilstalsohavingaprojectmanager(PM)inthesponsor’sowntimezone.REFERENCES1.In

Vivo,

Clinical

Trials:

Have

We

Finally

Reached

The

NewNormal?

(2022)

rma.com/IV146739/Clinical-Trials-Have-We-Finally-Reached-The-New-NormalPMs

can

facilitate

ongoing

cross-functional

conversationseasily

with

the

local

CTM

to

ensure

there

is

no

breakdownincommunication,whileensuringdedicatedresourceinthelocation

of

the

trial

to

maintain

progress.

As

part

of

this,

thereshould

also

be

clear

escalation

pathways

in

the

event

thatchallenges

arise

and

other

stakeholders

need

to

be

pulled

in.2.DIA,

How

China

is

Changing

the

Clinical

Development

Land-scape:

Implications

for

Global

Development

Strategy

(2019)/issue/october-2019/how-china-is-changing-the-clinical-development-land-scape/SCRIPASIA100

5SCRIPASIA100SCRIP

ASIA

100:

2022

PHARMACEUTICAL

SALESLATESTPHARMASALESLATESTPHARMASALESPHARMASALES%CHANGEPHARMASALES%CHANGERANK

COMPANYRANK

COMPANY($M)($M)1Takeda308421162987145701551245694284425441003983390838053139313129832898281525522331225922262219207420722055-5%2%26272829303132333435363738394041424344454647484950KyowaHakkoKirin1944188018651774165416511599153415111493141014061397137913291255123512331219121511871167115611121047-39%1%2AstellasLivzonPharmaceuticalGroupShijiazhuangYilingPharmaceuticalCo.,Ltd3OtsukaPharmaceuticalEisai-2%-17%6%19%6%4Celltrion5SunPharmaceuticalGlenmarkPharmaceuticalsTopconCorp.Towa-1%ShanghaiFosunPharmaceuticalGroup62%309%13%-13%-12%-92%27%0%7SinoBiopharmaceutical3%8SumitomoDainipponPharmaMitsubishiTanabePharma-9%17%2%Sawai9MeijiHoldingsSinovacBiotechLtd.BioconShanghaiPharmaceuticalGroupCo.,Ltd.10111213141516171819202122232425CSPCPharmaceuticalGroupLtd.20%0%CRDouble-CranePharmaceuticalsCo.,LtdAsahiKaseiPharmaJiangsuHengruiMedicineCo.Ltd.-22%22%-6%-1%5%Jiangsu

Hansoh

PharmaceuticalYuhanCorp-9%DrReddy's-6%AurobindoGCBiopharma(GreenCross)Beigene-1%Cipla98%25%-4%ShenzhenHepalinkPharmaceuticalGroupCo.,Ltd.SichuanKelunPharmaceuticalJoincarePharmaceuticalGroupIndustryCo.,Ltd.3%KPCPharmaceuticalInc.ZhejiangHuahaiPharmaceuticalCo.,Ltd.SamsungBioLogicsOno70%1%18%7%TorrentPharmaceuticals3SBioShandongBuchangPharmaceuticalsCo.,Ltd.-9%9%22%-30%-2%ZydusLifesciences(earlierCadilaHealthcare)TeijinPharmaSantenLupin-9%-5%4%ChongKunDangKwang-DongPharmaceuticalDaiichiSankyo-5%HarbinPharmaceuticalGroupCo.,Ltd.-77%6

SCRIPASIA100SCRIPASIA100SCRIP

ASIA

100:

2022

PHARMACEUTICAL

SALESLATESTPHARMASALESLATESTPHARMASALESPHARMASALES%CHANGEPHARMASALES%CHANGERANK

COMPANYRANK

COMPANY($M)($M)51525354555657585960616263646566676869707172737475LuyePharmaGroupLtd.103510349949839739348828678298227987917697527106756746666606586486406376356167%-2%-1%-10%46%-15%-8%-10%9%767778798081828384858687888990919293949596979899100TakaraBioInc.598594591561559557532524514501495494470468463448426398396396382374365355354-3%5%ZhuzhouQianjinPharmaceuticalCo.,Ltd.HanmiPharmDaewoongPharmaceuticalHisamitsuBoryung106%-15%-19%293%0%JeilPharmaceuticalKakenShanghaiRAASBloodProductsCo.,Ltd.YichangHECChangjiangPharmaceuticalCo.NipponShinyakuZhejiangConbaPharmaceuticalCo.,Ltd.JWPharmaceuticalCorporationZeriaPharmaceuticalsDongkookPharmKisseiKyorin9%ShandongLukangPharmaceuticalCo.,Ltd.-1%1%SSYGroupLimited19%-4%-16%15%40%-1%-73%-3%-3%-17%0JubilantPharmova(earlierJubilantLifeSciences)Il-DongPharm1%MochidaDong-AST-5%13%9%LaurusLabsLtd.WalvaxBiotechnologyCo.,Ltd.AlembicStridesPharmaZheijiangJingXinPharmaceuticalCo.,Ltd.HarbinGloriaPharmaceuticalsCo.,Ltd.-5%1%MegaLifesciencesPublicCo.Ltd.ShionogiCKLifeSciencesHutchisonChinaMediTechTorayIndustriesJapanLifelineCo.,Ltd.NipponKayakuHuonsCo.,Ltd.Torii20%-18%-15%-17%0%HualanBiologicalEngineering,Inc.MaruhoHKinno.N(formerlyCJHealthcare)PTKimiaFarma-28%5%JiangsuNHWAPharmaceuticalCo.,Ltd.-13%-26%-1JiangsuKanionPharmaceuticalCoLtdGuangxiWuzhouPharmaceuticalGroupCo.Ltd.13%-13%-1%JapanTobaccoInnoventBioSKBioscienceBettaPharmaceuticalsCo.,Ltd.2%SCRIPASIA100

7SCRIPASIA100CHINA

TOP

20

PHARMACEUTICALCOMPANIES

BY

SALESJAPAN

TOP

20

PHARMACEUTICALCOMPANIES

BY

SALES2022PHARMASALES($M)CHANGE2022PHARMASALES($M)CHANGEFROM2021(%BASIS)FROM2021(%BASIS)RANK

COMPANYRANK

COMPANYShanghaiFosun1456942843983390831392815255222262055188018651493140613971255123512331219118718802%3%12Takeda308421162987145701425441003805225920741944165115991534151111671047983-5%2%PharmaceuticalGroup23SinoBiopharmaceuticalAstellasShanghaiPharmaceuticalGroupCo.,Ltd.2%3OtsukaPharmaceuticalEisai-2%CSPCPharmaceuticalGroupLtd.420%-22%5%4-17%-9%JiangsuHengruiMedicineCo.Ltd.55SumitomoDainipponPharmaMitsubishiTanabePharmaAsahiKaseiPharmaOno6SichuanKelunPharmaceutical617%0%JoincarePharmaceuticalGroupIndustryCo.,Ltd.73%7ShandongBuchangPharmaceuticalsCo.,Ltd.8-9%4%81%HarbinPharmaceuticalGroupCo.,Ltd.99Santen-9%1011121314151617181920LivzonPharmaceuticalGroup1%1011121314151617181920KyowaHakkoKirinTopconCorp.Towa-39%309%13%-13%-12%-30%-77%-10%-15%-10%-16%ShijiazhuangYilingPharmaceuticalCo.,Ltd19%-92%0%SinovacBiotechLtd.CRDouble-CranePharmaceuticalsCo.,LtdSawaiJiangsu

Hansoh

PharmaceuticalBeigene-9%98%25%-4%18%22%7%MeijiHoldingsTeijinPharmaDaiichiSankyoHisamitsuShenzhenHepalinkPharmaceuticalGroupCo.,Ltd.KPCPharmaceuticalInc.ZhejiangHuahaiPharmaceuticalCo.,Ltd.NipponShinyakuKyorin9343SBio867LivzonPharmaceuticalGroupMochida7918

SCRIPASIA100SCRIPASIA100INDIA

TOP

10

PHARMACEUTICALCOMPANIES

BY

SALESSOUTH

KOREA

TOP

10

PHARMACEUTICALCOMPANIES

BY

SALES2022PHARMASALES($M)CHANGE2022PHARMASALES($M)CHANGEFROMFROM2021(%BASIS)RANK

COMPANYRANK

COMPANY2021(%BASIS)12SunPharmaceutical5512313129832898221920721654141012157986%22%-6%-1%9%12SamsungBioLogics233117741379132911561112103499470%6%DrReddy'sAurobindoCiplaCelltrion33YuhanCorp-6%-1%-2%-5%-2%-1%044GCBiopharma(GreenCross)ChongKunDangZydusLifesciences(earlierCadilaHealthcare)556Lupin-5%-1%27%7%6Kwang-DongPharmaceuticalHanmiPharm7GlenmarkPharmaceuticalsBiocon788DaewoongPharmaceuticalHKinno.N(formerlyCJHealthcare)9TorrentPharmaceuticals9658JubilantPharmova(earlierJubilantLifeSciences)10-4%10Boryung591106%SCRIPASIA100

9SCRIPASIA100The

world’s

leading

CROPowered

by

Healthcare

IntelligenceICONistheworld’s

largestpureplayclinicalresearchorganisation.From

moleculetoWe

commence

client

engagements

with

a

strategicconsultation,

delivered

byour

team

of

over

700consultants,to

identify

customsolutions,

eliminate

process

white

spaceand

identify

ef?ciencies

and

savings.

This

delivers

acrossthree

areas:medicine,we

advanceclinicalresearchprovidingoutsourceddevelopmentandcommercialisationservicesto

pharmaceutical,biotechnology,medicaldeviceandgovernmentandpublichealthorganisations.We

developnewinnovations,driveemergingtherapiesforwardandimprove

patientlives.ICONoffersthemostcomprehensivesuiteof

integrated

clinicaldevelopmentservicesintheindustry.

We’ve

designedfullycustomisablesolutionsto

helpourcustomersachievetheirgoalsacrossaseamlessdeliverymodelspanningtheirproduct’s

entirelifecycle.–

Robust

asset

development

consulting

fora

deeperunderstandingofdevelopmentpathways,assetacquisition/transfer

options

and

access

to

scienti?cexpertise

across

disciplines

forad

hoc

support.–

A

network

ofinternational

experts

delivering

superiorregulatory

and

quality

assurance

strategies,

submissions,and

support

to

expedite

drug

and

medical

devicedevelopment

and

manage

ongoing

global

compliance.–

Integratedsolutions

to

demonstrate

the

value

ofproductsand

support

global

brand

success

from

dedicated

real-world

evidence,

pricing,

market

access,

reimbursement,health

economics,

and

medical

communications

experts.Our

focus

is

on

delivering

Healthcare

Intelligence

tocustomers

to

address

the

full

spectrumofclinicalThis

consultative-led

approach,

the

breadth

ofourcapabilities

and

advanced

digital

and

data

capabilitiesenables

us

to

deliver

seamless,

integratedservices.development

challenges,

notjust

point

ofservice

delivery.The

synthesis

ofour

experience,

expertise,

best

practices,technology

and

data

provides

patient-centric

processes,commercially

optimised

for

global

success,

and

is

drivingtransformation

oftrials

to

improve

R&DROI.ICON

hasestablished

relationships

with

a

majority

ofthe

world’s

toppharmaceutical

and

biotech

companies,

offering:Consultative

lead

engagementAsset

Development

Regulatory

Commercial

PositioningGlobally

scaled

expertise

and

solutions

for

all

customersand

patients.ICON

is:–

Worldleader

in

Functional

Service

Provision

(FSP)–

Global

number

2

in

full-service

Ph2/3

clinical

research–

Global

number

2

in

Early

Phase

clinical

research–

Global

number

3

in

LatePhase

&

RWESeamless,

integrated

service

deliveryAdvanced

digital

and

data

capabilities–

Global

number

4

in

Central

&

SpecialityLaboratory

ServicesClinical

focus:

no

ownership

from

parent

organisationand

no

distractions

from

‘near

adjacencies’

means

wearecompletely

committed

to

customers’clinical

developmentprograms.Empirically-based

guidance

and

built-to-specmodels

and

solutions

across

every

phase

of

clinicalresearch

and

lifecycle

managementFlexible

partnership

models

and

governance

structuresensure

transparent

communications.

Regardlessofthe

sizeofyour

organisation

or

your

project,

wework

your

way.Strategy-driven

delivery:

AtICON,

weknow

thatclinicalresearch

nowrequires

a

more

comprehensive,

strategy-driven

delivery.

Our

approach

is

to

proactively

guide

clientstowardsthe

most

effective,

ef?cient

solution

across

allmodalities

ofresearch.Intelligent,

informed

decisions

todrive

actions

thataccelerate

the

development

of

drugs

and

devices10

SCRIPASIA100SCRIPASIA100Decentralised

clinical

trial

solutions:

Clinical

researchshould

engage

with

patients

wherever

theyare.ICONhas

all

the

service

components

to